A Study to Evaluate the Efficacy and Safety of AD-221 and AD-221A
NCT ID: NCT05131997
Last Updated: 2022-07-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
290 participants
INTERVENTIONAL
2021-11-16
2022-06-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Safety and Pharmacokinetics of AD-221 Compared to Coadministration of AD-221A and AD-221B
NCT05202405
A Study to Evaluate the Efficacy and Safety of AD-218
NCT05400317
Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022
NCT06448962
A Clinical Trial to Evaluate the Efficacy and Safety of CKD-391 and CKD-331 in Patients With Primary Hypercholesterolemia
NCT05657574
A Study to Evaluate the Efficacy and Safety of Co-administration of AD-2281 and AD-2282
NCT06747936
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AD-221
AD-221, Placebo of AD-221A, AD-221B and AD-221C
AD-221
PO, Once daily(QD), 8 weeks
AD-221A
AD-221A, Placebo of AD-221, AD-221B and AD-221C
AD-221A
PO, Once daily(QD), 8 weeks
AD-221B
AD-221B, Placebo of AD-221, AD-221A and AD-221C
AD-221B
PO, Once daily(QD), 8 weeks
AD-221C
AD-221C, Placebo of AD-221, AD-221A and AD-221B
AD-221C
PO, Once daily(QD), 8 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AD-221
PO, Once daily(QD), 8 weeks
AD-221A
PO, Once daily(QD), 8 weeks
AD-221B
PO, Once daily(QD), 8 weeks
AD-221C
PO, Once daily(QD), 8 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects with primary hypercholesterolemia
Exclusion Criteria
* Other exclusions applied
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Addpharma Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sang Hak Lee, M.D., Ph.D
Role: PRINCIPAL_INVESTIGATOR
Yonsei University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Yonsei University Hospital
Seoul, Seodaemun-gu, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AD-221P3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.